Abstract
Surfactant proteins (SPs), originally known as human lung surfactants, are essential to respiratory structure and function. There are 4 subtypes, SP-A, SP-B, SP-C and SP-D, with SP-A and SP-D having immunological functions, and SP-B and SP-C having physicochemical properties that reduce the surface tension at biological interfaces. In this experiment, the expressions of SP-A, SP-B, SP-C and SP-D in lung neoplastic lesions induced by N-bis (2-hydroxypropyl) nitrosamine (DHPN) and inflammatory lesions due to quartz instillation were examined and compared immunohistochemically. Formalin fixed paraffin embedded (FFPE) lung samples featuring inflammation were obtained with a rat quartz instillation model, and neoplastic lesions, hyperplasias and adenomas, were obtained with the rat DHPN-induced lung carcinogenesis model. In the rat quartz instillation model, male 10-week old F344 rats were exposed by intratracheal instillation (IT) to quartz at a dose of 2 mg/rat suspended in saline (0.2 ml) on day 0, and sacrificed on day 28. Lung tumorigenesis in F344 male rats was initiated by DHPN in drinking water for 2 weeks, and the animals were then sacrificed in week 30. Lung proliferative lesions, hyperplasias and adenomas, were observed with DHPN, and inflammation was observed with quartz. The expressions of SP-A, SP-B, SP-C and SP-D were examined immunohistochemically. SP-B and SP-C showed strong expression in lung hyperplasias and adenomas, while SP-A and SP-D were observed in mucus or exudates in inflammatory alveoli. These results suggest the possibility that SP-B and SP-C are related to lung tumorigenesis.
Keywords: urfactant protein, DHPN, quartz, rat, lung, tumor
Introduction
Surfactant proteins (SPs), originally known as human lung surfactants, are essential to proper respiratory structure and function. They are unique in composition, consisting of about 90% lipids, mostly phospholipids, and 8–10% surfactant-associated proteins1. SPs line the alveolar surface, and reduce surface tension at the air–fluid interface2. Pulmonary surfactant is stored mainly in type II alveolar epithelial cells in the form of densely packed bilayers called lamellar bodies that are secreted and efficiently transferred to the interface1, 2. There are 4 subtypes, SP-A, SP-B, SP-C and SP-D, the characteristics of which are summarized in table 1; the table contents were obtained from the literature and modified for use here1, 3, 4. There are many reports regarding the role of SPs in lung inflammation or chronic obstructive pulmonary disease (COPD). However, the expression of SP-A, SP-B, SP-C or SP–D in lung tumors has received only limited attention.
Table 1. Characteristics of SP-A, SP-B, SP-C and SP-D.

Previously, in order to establish an appropriate bioassay for detection of promoting potential for lung tumor development after intratracheal instillation (IT) of fine particles in rats, sequential histopathological changes up to 30 weeks were examined after initiation of lung tumorigenesis with 0.1% N-bis (2-hydroxypropyl) nitrosamine (DHPN) in drinking water for 2 weeks in male F344 rats5,6,7. It has been reported that activating mutations of the Kras gene at codon 12 are detected in almost 50% of rat lung neoplastic lesions induced by a carcinogen8. Furthermore, we previously examined the lung toxicity of fine particles of various materials in an in vivo bioassay using an IT approach5, 7, 9. In humans, coal miners and building construction workers who are exposed to quartz dust demonstrate obstructive and restrictive loss of lung capacity10, as well as COPD11, 12. This is associated with an inflammatory cell responses characterized by alveolitis with recruitment of inflammatory cells, particularly neutrophils, and may result in pulmonary fibrosis and impaired lung function13. IT of quartz into rats produces inflammatory reactions followed by histological changes characteristic of lung fibrosis14, similar to human conditions. With a dose of 2 mg/rat IT, fine particles of quartz caused toxicity with severe inflammatory changes characterized by neutrophil infiltration and edema after 28 days6. In the present study, the expressions of SP-A, SP-B, SP-C and SP-D in lung neoplastic lesions induced by DHPN and in inflammatory lesions caused by quartz were examined and compared immunohistochemically.
Materials and Methods
Animals
Experimental animals were maintained in the Division of Animal Experiments, Life Science Research Center, Kagawa University, according to the Institutional Regulations for Animal Experiments. All were housed in polycarbonate cages with white wood chips for bedding and given free access to drinking water and a basal diet, CE-2 (CLEA Japan Inc., Tokyo, Japan), under controlled conditions of humidity (60 ± 10%), lighting (12-h light/dark cycle) and temperature (24 ± 2°C).
Tissue Samples
Formalin fixed paraffin embedded (FFPE) lung samples featuring inflammation were obtained with the rat quartz instillation model on day 289 and FFPE lung samples including neoplastic lesions, hyperplasias and adenomas, were obtained with the rat DHPN-induced lung carcinogenesis model15. Briefly, in the rat quartz instillation model, male 10-week old F344/DuCrlCrj rats (Charles River Laboratories Japan, Inc., Kanagawa, Japan) were exposed by IT to quartz with a particle diameter of less than 7 µm (DQ-12, DMT GmbH & Co. KG, Germany) at a dose of 2 mg/rat suspended in saline (0.2 ml) (Isotonic sodium chloride solution, Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan) on day 0 and sacrificed on day 289. For the rat DHPN induced lung carcinogenesis model, male 6-week old F344/DuCrlCrlj rats were given 0.1% DHPN (Nacalai Tesque Inc., Kyoto, Japan) in drinking water for 2 weeks and sacrificed in week 30.
At autopsy in both experiments, the lungs were removed, including the trachea and heart, infused through the trachea with 10% phosphate buffered formalin, rinsed in the same fixative and then immersed in the fixative for approximately 48 h. Slices were then routinely processed for embedding in paraffin for histopathological examination.
Histopathological analysis
Lung lesions from the rat DHPN-induced lung carcinogenesis model were categorized as bronchioloalveolar hyperplasia (hyperplasia) and bronchioloalveolar adenoma (adenoma) in accordance with the established criteria given in the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND)16. In detail, bronchioloalveolar hyperplasia was diagnosed from the finding of solitary or multiple, segmental (cone-shaped) foci of increased cellularity, a lack of strongly convex or spherical borders, the bronchioloalveolar architecture still being detectable and epithelial cells, usually a single layer, still being dominant and the cause of hypercellularity. Bronchioloalveolar adenomas were frequently located at the lung periphery and usually small in size (less than 3–4 mm in diameter), featuring well-circumscribed areas of high epithelial cell density, usually with a strongly convex border, an underlying alveolar architecture obscured to various degrees, sharp demarcation from the surrounding tissue and relatively uniform neoplastic epithelial cells with mitotic figures rare or absent. Small foci of mild atypia were sometimes present, and occasionally extension into adjacent bronchioles was evident.
For SP-A, SP-B and SP-C, all immunohistochemical staining processes from deparaffinization to counterstaining with hematoxylin were performed automatically using the Ventana DiscoveryTM staining system (Ventana Medical Systems, Tucson, AZ, USA). For SP-D, immunostaining was performed by hand with an EnVisionTM kit (DAKO, Tokyo, Japan). Antigen retrieval was performed with 3 methods using RiboCC solution (lot. D02647, Ventana Medical Systems, Tucson, AZ, USA) for SP-A and SP-C, CC1 solution (lot. D06855, Ventana Medical Systems, Tucson, AZ, USA) for SP-B and Target Retrieval Solution (DAKO, Tokyo, Japan) for SP-D. The details of the SP-A, SP-B, SP-C and SP–D antibodies used in the experiments are summarized in Table 2. The expressions for each marker, SP-A, SP-B, SP-C and SP-D, were evaluated as none (−), weak (+) and strong (++) compared with the histopathological normal area without inflammation or a proliferative lesion in the same specimens.
Table 2. Details of Antibody and Immunostaining.

Results
Inflammatory lesions were observed in the lungs with the rat quartz instillation models on day 28. The main findings were neutrophil infiltration in the walls and spaces of the alveoli, pulmonary edema, pulmonary fibrosis, alveolar macrophage infiltration and restructuring of the alveolar walls and granulation-like changes with giant cells and macrophages in the alveoli. For evaluation of the expressions of the SPs, the histopathological normal area of the lungs treated with quartz was used as a control (see Figure 1-D, E, F, I and J). The lesions were observed to be strongly positive for SP-A in the mucus in alveoli (see Figure 1-B), weakly positive for SP-B in the mucus and strongly positive for SP-B in the alveolar epithelial cells and bronchial epithelial cells (see Figure 1-C), weakly positive for SP-C in the mucus and strongly positive for SP-C in the alveolar epithelial cells (see Figure 1-G), and strongly positive for SP-D in the mucus and partially positive for SP-D in the alveolar epithelial cells (see Figure 1-H). The bronchiolar epithelial cells after treatment with quartz were strongly positive (++) for SP-B and weakly positive (+) for SP-A, SP-C and SP-D (see Figure 2). DHPN-induced proliferative lesions, hyperplasias and adenomas, in F344 rat lungs were weakly positive (+) for SP-A (see Figure 3-B), strongly (++) positive for SP-B (see Figure 3-C), strongly positive (++) for SP-D (see Figure 3-G), and almost negative (−) for SP-D, although the normal alveolar epithelium was also positive (see Figure 3-H). For evaluation of the expressions the SPs, the histopathological normal area of the lungs treated with DHPN was used as a control (see Figure 3-D, E, F, I and J). The findings for the expressions in the control areas were similar (Table 3).
Fig. 1.
Histopathological and immunohistochemical findings for inflammatory lesions induced by quartz in the F344 rat lung (×200). A and D, H.E.; B and E, SP-A; C and F, SP-B; G and I, SP-C; H and J, SP-D. A, B, C, G and H, inflammatory lesions; D, E, F, I and J, noninflammatory lesions (control). Note the strong positive reactions in the mucus in the alveoli in Fig. 1-B, strongly positive staining of alveolar epithelial cells and bronchial epithelial cells in Fig. 1-C, alveolar epithelial cells in Fig. 1-G and mucus in the alveoli in Fig. 1-H.
Fig. 2.
Immunohistochemical findings for bronchiolar epithelial cells in the F344 rat lung after quartz exposure (×200). A, weak positivity (+) for SP-A; B, strong positivity (++) for SP-B; C, weak positivity (+) for SP-C; D, negative for SP-D.
Fig. 3.
Histopathological and immunohistochemical findings for DHPN-induced proliferative lesions, hyperplasias and adenomas, in the F344 rat lung (×200). A and D, H.E.; B and E, SP-A; C and F, SP-B; G and I, SP-C; H and J, SP-D. A, B, C, G and H, proliferative lesions; D, E, F, I and J, nonproliferative lesions (control). Note the weak positivity (+) for SP-A in Fig. 1-B, strong positivity (++) for SP-B in Fig. 1-C, strong positivity (++) for SP-D in Fig. 1-G and almost negative (−) staining for SP-D in Fig. 1-H.
Table 3. Summary of the Expressions of SP-A, SP-B, SP-C and SP-D.

The immunohistochemical results are summarized in Table 3. The expressions of SP-A and SP-D were strongly positive in the mucus in the alveoli with inflammatory changes. SP-B and SP-C showed strong positivity in the proliferative lesions, hyperplasias and adenomas, whereas the expressions of SP-A and SP-D were weak and lacking, respectively.
Discussion
In the present experiment, the expressions of SP-A and SP-D appeared to be similar, with strong positivity in the mucus in alveoli of inflammatory lesions induced by quartz. SP-A and SP-D both play significant roles in surfactant homeostasis and pulmonary immunity and are known to bind to a range of microbial pathogens that invade the lungs and target them for phagocytic clearance by resident alveolar macrophages. They are also involved in the removal of apoptotic and necrotic cells and subsequent resolution of pulmonary inflammation17, 18In vivo studies have shown that SP-A regulates responses involved in initiation and potentiation of inflammation by regulating the production of proinflammatory cytokines, such as tumor necrosis factor α (TNF-α), in response to lipopolysaccharide (LPS) or by accelerating the clearance of a variety of pathogens19,20,21. Alveolar macrophages are thought to play a critical role in host defense in the lung22. In vitro, both SP-A and SP-D can stimulate alveolar macrophages to generate oxygen radicals, as measured by chemiluminescence23, 24. As hydrophilic surfactant proteins, they participate in the innate immune response by binding to bacterial and viral pathogens and activating alveolar macrophages2. The strong expression of SP-A and SP-D in the present experiment suggests activation of macrophages to deal with instilled quartz particles.
Expression of SP-A was weak in the proliferative lesions in the present experiment, and this was noteworthy because SP-A has been used as a serous marker for human lung cancer in clinical examinations in Japan. Lung cancer is the leading cause of cancer-related deaths worldwide in both developing and developed regions25, 26. In one study, SP-A was expressed in approximately 49% of primary non–small cell lung carcinomas27. It was found to be closely associated with some specific subtypes of adenocarcinoma28, 29. Some studies have suggested that SP-A might have a role in suppressing lung cancer progression, and SP-A expression by tumor cells leads to recruitment and activation of NK cells and tumor-associated macrophages19. In another study, activating mutations of the Kras gene at codon 12 were reported in 47% of lesions induced by DHPN in the F344 rat8. Overexpression of oncogenic Kras leads to activation of the NF-κB pathway, which appears to be required for the development of tumors in a mouse model of lung adenocarcinoma30. SP-A has been shown to inhibit LPS-induced NF-κB, TNF-α production, inducible NO synthase protein expression or activity and, in the presence of diverse stimuli, NADPH oxidase in immunocompetent cells31. In the present experiment, only hyperplasias and adenomas, not adenocarcinomas, were observed as neoplastic lesions, and this suggests that Kras mutations and activation of NF-κB might be associated with later stages of malignancy.
SP-C, which is a specific marker of type II epithelial cells in the lung3, showed the strong positivity in proliferative lesions in the present experiment. SP-B and SP-C have physicochemical properties that reduce the surface tension of biological interfaces4. In the lung tumorigenesis model induced by a mixture of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene (BaP) in A/J mice, pulmonary SP-A, SP-B, and SP-C were identified in the mouse lung, but only the SP-C levels increased in carcinogen-treated versus untreated mice32.
In the present experiment, SP-B was also positive in neoplastic lesions. The main function of SP-B is to accelerate the formation of a surface-active film composed of phospholipids at the air-water interface by increasing the adsorption rate33, 34. SP-B has anti-inflammatory properties and may be involved in protecting the lung against oxidative stress33, 35, 36 and circulating pro–SP-B is reported to be a biomarker for early detection of non–small-cell lung cancer (NSCLC)37. On synthesis, pro-SP-B quickly undergoes proteolytic cleavage by cysteine proteases in the endoplasmic reticulum, resulting in the production and secretion of a 9-kD noncollagenous hydrophobic SP-B, which is the functional mature form38. Lung tumor cells, especially adenocarcinomas, have dysregulated SP-B synthesis, leading to the overexpression of pro-SP-B with a muted ability to posttranslationally modify the precursor into the mature hydrophobic form39, 40.
As described in the introduction page, SPs are stored in the lung type II epithelial cells, and in the present experiment, the lung proliferative lesions, hyperplasias and adenomas, were also positive for SPs. This result suggests the lung hyperplasias and adenomas would have their origin in type II alveolar cells.
In our previous experiment, napsin A was determined to be a good marker for detection of hyperplastic lesions linked to actual neoplasia41. Napsin A is an aspartic proteinase involved in the maturation of SP-B42 and is expressed in the cytoplasm of type II pneumocytes and Clara cells in the lung and also in the proximal tubular renal epithelium and exocrine pancreas43, 44. Human clinical studies suggest that napsin A may be a highly specific marker for adenocarcinoma in the lung45, 46. However, when there is a need to rule out lung metastasis from other organs, for example, from renal, thyroid or endometrial carcinomas, implementation of other biologically specific markers should be considered45. In the present experiment, the positive area of SP-B seemed not to correspond completely with that of napsin A.
In conclusion, SP-B and SP-C showed strong expression in lung hyperplasias and adenomas and expression of SP-A and SP-D was observed in mucus or exudates in inflammatory alveoli. These results suggest the possibility that SP-B and SP-C are linked to lung tumorigenesis.
Acknowledgments
This work was supported in part by Grants-in-Aid for Chemical Risk Research from the Ministry of Health, Labour and Welfare (MHLW) of Japan. We thank Dr. Malcolm A. Moore for help in critical reading of this manuscript.
Declaration of Conflicting Interests: We have no conflicts of interest to be declared.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.
References
- 1.Pérez-Gil J, and Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta. 1408: 203–217. 1998. [DOI] [PubMed] [Google Scholar]
- 2.Olmeda B, Umstead TM, Silveyra P, Pascual A, López-Barneo J, Phelps DS, Floros J, and Pérez-Gil J. Effect of hypoxia on lung gene expression and proteomic profile: insights into the pulmonary surfactant response. J Proteomics. 101: 179–191. 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Archer F, Jacquier E, Lyon M, Chastang J, Cottin V, Mornex JF, and Leroux C. Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro. Am J Respir Cell Mol Biol. 36: 534–540. 2007. [DOI] [PubMed] [Google Scholar]
- 4.Perez-Gil J, and Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology (Bethesda). 25: 132–141. 2010. [DOI] [PubMed] [Google Scholar]
- 5.Yokohira M, Kuno T, Yamakawa K, Hashimoto N, Ninomiya F, Suzuki S, Saoo K, and Imaida K. An intratracheal instillation bioassay system for detection of lung toxicity due to fine particles in f344 rats. J Toxicol Pathol. 22: 1–10. 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yokohira M, Takeuchi H, Yamakawa K, Saoo K, Ikeda M, Matsuda Y, Zeng Y, Hosokawa K, Maeta H, and Imaida K. Establishment of a bioassay system for detection of lung toxicity due to fine particle instillation: Sequential histopathological changes with acute and subacute lung damage due to intratracheal instillation of quartz in F344 male rats. J Toxicol Pathol. 18: 13–18. 2005. [Google Scholar]
- 7.Yokohira M, Takeuchi H, Yamakawa K, Saoo K, Matsuda Y, Zeng Y, Hosokawa K, and Imaida K. Bioassay by intratracheal instillation for detection of lung toxicity due to fine particles in F344 male rats. Exp Toxicol Pathol. 58: 211–221. 2007. [DOI] [PubMed] [Google Scholar]
- 8.Yamakawa K, Kuno T, Hashimoto N, Yokohira M, Suzuki S, Nakano Y, Saoo K, and Imaida K. Molecular analysis of carcinogen-induced rodent lung tumors: Involvement of microRNA expression and Krαs or Egfr mutations. Mol Med Rep. 3: 141–147. 2010. [DOI] [PubMed] [Google Scholar]
- 9.Yokohira M, Kuno T, Yamakawa K, Hosokawa K, Matsuda Y, Hashimoto N, Suzuki S, Saoo K, and Imaida K. Lung toxicity of 16 fine particles on intratracheal instillation in a bioassay model using f344 male rats. Toxicol Pathol. 36: 620–631. 2008. [DOI] [PubMed] [Google Scholar]
- 10.Tjoe-Nij E, de Meer G, Smit J, and Heederik D. Lung function decrease in relation to pneumoconiosis and exposure to quartz-containing dust in construction workers. Am J Ind Med. 43: 574–583. 2003. [DOI] [PubMed] [Google Scholar]
- 11.Repine JE, Bast A, and Lankhorst I. Oxidative Stress Study Group Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 156: 341–357. 1997. [DOI] [PubMed] [Google Scholar]
- 12.Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, Venge P, Laitinen LA, and Brattsand R. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis. 148: 1226–1232. 1993. [DOI] [PubMed] [Google Scholar]
- 13.Bowden DH, and Adamson IY. The role of cell injury and the continuing inflammatory response in the generation of silicotic pulmonary fibrosis. J Pathol. 144: 149–161. 1984. [DOI] [PubMed] [Google Scholar]
- 14.Benson SC, Belton JC, and Scheve LG. Regulation of lung fibroblast proliferation and protein synthesis by bronchiolar lavage in experimental silicosis. Environ Res. 41: 61–78. 1986. [DOI] [PubMed] [Google Scholar]
- 15.Yokohira M, Hashimoto N, Yamakawa K, Suzuki S, Saoo K, Kuno T, and Imaida K. Lung carcinogenic bioassay of CuO and TiO(2) nanoparticles with intratracheal instillation using F344 male rats. J Toxicol Pathol. 22: 71–78. 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, Rosenbruch M, Tellier P, and Wohrmann T. Proliferative and nonproliferative lesions of the rat and mouse respiratory tract. Toxicol Pathol. 37(Suppl): 5S–73S. 2009. [DOI] [PubMed] [Google Scholar]
- 17.Moliva JI, Rajaram MV, Sidiki S, Sasindran SJ, Guirado E, Pan XJ, Wang SH, Ross P, Jr , Lafuse WP, Schlesinger LS, Turner J, and Torrelles JB. Molecular composition of the alveolar lining fluid in the aging lung. Age (Dordr). 36: 9633 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jakel A, Qaseem AS, Kishore U, and Sim RB. Ligands and receptors of lung surfactant proteins SP-A and SP-D. Front Biosci (Landmark Ed). 18: 1129–1140. 2013; . [DOI] [PubMed] [Google Scholar]
- 19.Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, and Nishioka Y. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol. 182: 1843–1853. 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, and Wright JR. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol. 278: L840–L847. 2000. [DOI] [PubMed] [Google Scholar]
- 21.LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, and Korfhagen T. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest. 103: 1015–1021. 1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, and Korfhagen TR. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol. 165: 3934–3940. 2000. [DOI] [PubMed] [Google Scholar]
- 23.van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, and van Golde LM. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol. 2: 91–98. 1990. [DOI] [PubMed] [Google Scholar]
- 24.Van Iwaarden JF, Shimizu H, Van Golde PH, Voelker DR, and Van Golde LM. Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J. 286: 5–8. 1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Siegel R, Ward E, Brawley O, and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61: 212–236. 2011. [DOI] [PubMed] [Google Scholar]
- 26.Imaida K, Yokohira M, and Kuno T. Detection of carcinogenic and modifying potentials by test compounds using a mouse lung carcinogenesis bioassay. J Toxicol Pathol. 20: 117–123. 2007. [Google Scholar]
- 27.Bejarano PA, Baughman RP, Biddinger PW, Miller MA, Fenoglio-Preiser C, al-Kafaji B, Di Lauro R, and Whitsett JA. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 9: 445–452. 1996. [PubMed] [Google Scholar]
- 28.Kaufmann O, and Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 36: 8–16. 2000. [DOI] [PubMed] [Google Scholar]
- 29.Jie-Liu, Li XY, Zhao YQ, Liu RQ, Zhang JB, Ma J, Chen LJ, and Hu XF. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations. Pathol Res Pract. 210: 176–181. 2014. [DOI] [PubMed] [Google Scholar]
- 30.Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, and Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 462: 104–107. 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Moulakakis C, Adam S, Seitzer U, Schromm AB, Leitges M, and Stamme C. Surfactant protein A activation of atypical protein kinase C zeta in IkappaB-alpha-dependent anti-inflammatory immune regulation. J Immunol. 179: 4480–4491. 2007. [DOI] [PubMed] [Google Scholar]
- 32.Kassie F, Anderson LB, Scherber R, Yu N, Lahti D, Upadhyaya P, and Hecht SS. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-induced alterations in protein levels. Cancer Res. 67: 6502–6511. 2007. [DOI] [PubMed] [Google Scholar]
- 33.Um SJ, Lam S, Coxson H, Man SF, and Sin DD. Budesonide/formoterol enhances the expression of pro Surfactant Protein-B in lungs of COPD patients. PLoS ONE. 8: e83881 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Whitsett JA, Ohning BL, Ross G, Meuth J, Weaver T, Holm BA, Shapiro DL, and Notter RH. Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr Res. 20: 460–467. 1986. [DOI] [PubMed] [Google Scholar]
- 35.Tokieda K, Ikegami M, Wert SE, Baatz JE, Zou Y, and Whitsett JA. Surfactant protein B corrects oxygen-induced pulmonary dysfunction in heterozygous surfactant protein B-deficient mice. Pediatr Res. 46: 708–714. 1999. [DOI] [PubMed] [Google Scholar]
- 36.Miles PR, Bowman L, Rao KM, Baatz JE, and Huffman L. Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages. Am J Physiol. 276: L186–L196. 1999. [DOI] [PubMed] [Google Scholar]
- 37.Sin DD, Tammemagi CM, Lam S, Barnett MJ, Duan X, Tam A, Auman H, Feng Z, Goodman GE, Hanash S, and Taguchi A. Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol. 31: 4536–4543. 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Guttentag S, Robinson L, Zhang P, Brasch F, Bühling F, and Beers M. Cysteine protease activity is required for surfactant protein B processing and lamellar body genesis. Am J Respir Cell Mol Biol. 28: 69–79. 2003. [DOI] [PubMed] [Google Scholar]
- 39.Khoor A, Whitsett JA, Stahlman MT, Olson SJ, and Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol. 30: 695–700. 1999. [DOI] [PubMed] [Google Scholar]
- 40.O’Reilly MA, Gazdar AF, Clark JC, Pilot-Matias TJ, Wert SE, Hull WM, and Whitsett JA. Glucocorticoids regulate surfactant protein synthesis in a pulmonary adenocarcinoma cell line. Am J Physiol. 257: L385–L392. 1989. [DOI] [PubMed] [Google Scholar]
- 41.Yokohira M, Kishi S, Yamakawa K, Nakano Y, Ninomiya F, Kinouch S, Tanizawa J, Saoo K, and Imaida K. Napsin A is possibly useful marker to predict the tumorigenic potential of lung bronchiolo-alveolar hyperplasia in F344 rats. Exp Toxicol Pathol. 66: 117–123. 2014. [DOI] [PubMed] [Google Scholar]
- 42.Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, and Peric M. IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 7: 165 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Bishop JA, Sharma R, and Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 41: 20–25. 2010. [DOI] [PubMed] [Google Scholar]
- 44.Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, and Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 118: 441–449. 2010. [DOI] [PubMed] [Google Scholar]
- 45.Kadivar M, and Boozari B. Applications and limitations of immunohistochemical expression of “Napsin-A” in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol. 21: 191–195. 2013. [DOI] [PubMed] [Google Scholar]
- 46.Masai K, Tsuta K, Kawago M, Tatsumori T, Kinno T, Taniyama T, Yoshida A, Asamura H, and Tsuda H. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 21: 292–297. 2013. [DOI] [PubMed] [Google Scholar]



